The detection levels for HER2 biomarker using the three technologies ranged from 0.1 fM to 20 pM, which is smaller than the HER2 blood levels present in cancer patients: 15 to 75 ng/mL (81.1 pM to 0.4 nM) [88]. Here, ERBB2 is linked to cancer.